Anthrax vaccine adsorbed

Anthrax vaccine adsorbed, sold under the brand name Biothrax among others, is a <a href="/facts/Vaccine/QcXzLug2">vaccine</a> intended to provide <a href="/facts/Acquired_immunity/bc7zT1Jo">acquired immunity</a> against <a href="/facts/Bacillus_anthracis/suoM7vhx">Bacillus anthracis</a>.
Anthrax vaccine adsorbed originated in studies done in the 1950s and was first licensed for use in humans in 1970. In the US, the principal purchasers of the vaccine are the <a href="/facts/United_States_Department_of_Defense/dWAvf7e3">Department of Defense</a> and <a href="/facts/Department_of_Health_and_Human_Services/eS90vYmd">Department of Health and Human Services</a>. Ten million courses (60 million doses) of the vaccine have been purchased for the US <a href="/facts/Strategic_National_Stockpile/H0u9uvBw">Strategic National Stockpile</a> in anticipation of the need for mass vaccinations owing to a future <a href="/facts/Bio-terrorist/YW2rmVls">bio-terrorist</a> anthrax attack. The product has attracted some controversy owing to alleged adverse events and questions as to whether it is effective against the inhalational form of anthrax.

Anthrax vaccine adsorbed open-in-new

Anthrax vaccine adsorbed